Potential for fundamentally treating osteoarthritis by blocking the secretory phenotype that promotes joint aging
Background
Osteoarthritis (OA) is a major degenerative joint disease that reduces the quality of life for the elderly population worldwide. As the aging population increases rapidly, the number of patients is also increasing rapidly, but existing treatments are limited to pain control and short-term inflammation relief. For patients in the late stages with cartilage loss, there are no options other than artificial joint replacement. These limitations arise because the fundamental causes of OA, cartilage degradation and inflammation, are not targeted at the cellular and molecular levels. In this regard, the medical community is paying attention to the phenomenon in which senescent cells contaminate the microenvironment within the joint. Senescent cells maintain metabolic activity even after cell proliferation stops and continuously release harmful signaling substances to surrounding tissues. As a result, the accumulation of senescent chondrocytes and macrophages disrupts joint homeostasis and leads to cartilage destruction.
Key Findings
The key pathogenic mechanism induced by cellular senescence is the senescence-associated secretory phenotype (SASP). Pro-inflammatory cytokines, chemokines, and proteases secreted by senescent cells maintain chronic inflammation in the joint and induce extracellular matrix (ECM) degradation. In this process, disruption of intracellular signaling pathways is also observed. The NF-κB, MAPK/p38, mTOR, and JAK/STAT pathways are activated, while the AMPK pathway, which inhibits inflammation, is deactivated.
Recent studies have identified pharmacological and genetic alternatives to control these SASP-related pathways. The first is small molecule compounds such as anakinra, metformin, and rapamycin. These compounds inhibit the interleukin-1 (IL-1) receptor or control cellular metabolism and the mTOR pathway, thereby reducing the production of inflammatory factors and protecting cartilage tissue. The second is microRNA (miRNA) regulation and CRISPR/Cas9 technology. These genetic tools block the expression of SASP factors at the transcriptional level, providing a fundamental therapeutic alternative.
Significance and Prospects
This discovery lays the foundation for shifting the OA treatment paradigm from symptom relief to the development of disease-modifying osteoarthritis drugs (DMOADs). By presenting clear molecular targets, cellular senescence and SASP, the possibility of delaying or stopping cartilage destruction has been confirmed.
However, several challenges must be overcome before actual clinical application. When small molecule compounds are administered systemically, there are concerns about metabolic side effects or inhibition of normal cell proliferation in healthy organs other than the joint. In particular, the safety of high-dose administration of metformin or rapamycin remains to be established. Gene therapy also requires optimization of drug delivery systems to rapidly and safely deliver therapeutic genetic material into chondrocytes. Future research will focus on improving local delivery performance and verifying safety.
As patients age, cellular senescence results in senescence-associated secretory phenotype (SASP). The SASP results in secretion of pro-inflammatory cytokines, chemokines, and proteases that drive chronic inflammation and cartilage degradation in osteoarthritis (OA). Accumulation of senescent chondrocytes and macrophages activates key signaling pathways such as NF-κB, MAPK/p38, mTOR, AMPK, and JAK/STAT, leading to sustained inflammation and extracellular matrix (ECM) breakdown. Recent studies have identified pharmacological and gene-based approaches that modulate SASP-related pathways. Small molecules such as anakinra, metformin, and rapamycin show potential in reducing inflammation and preserving cartilage, while microRNA modulation and CRISPR/Cas9 editing provide emerging means to regulate SASP factors at the transcriptional level. This review summarizes the molecular mechanisms by which the SASP contributes to OA pathogenesis and highlights novel therapeutic strategies aimed at attenuating inflammation, maintaining cartilage integrity, and mitigating disease progression.
This study provides a practical starting point for addressing the long-standing unmet needs in the osteoarthritis treatment market. The pharmaceutical industry can develop unique intra-articular injections in conjunction with drug delivery technologies specialized for local injection into the joint. Specifically, this involves loading SASP inhibitors such as metformin or rapamycin into biocompatible carriers such as hyaluronic acid or hydrogels. By directly administering this complex formulation to the knee joint, it is possible to minimize systemic side effects and achieve clinical application by slowly releasing the drug for 6 months to 1 year, slowing the rate of joint wear. Furthermore, in the case of CRISPR-based gene therapy, it can be commercialized as a local gene therapy that precisely targets only senescent chondrocytes in the joint cavity using non-viral nanoparticles, and is expected to become a core portfolio of the next-generation bio-pharmaceutical industry.